Skip to main content
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 2007 Dec 19;46(2):727–731. doi: 10.1128/JCM.01540-07

Simultaneous Detection of Chlamydophila pneumoniae and Mycoplasma pneumoniae by Use of Molecular Beacons in a Duplex Real-Time PCR

Karolina Gullsby 1, Martin Storm 2, Kåre Bondeson 2,*
PMCID: PMC2238133  PMID: 18094125

Abstract

A real-time PCR was designed for detection of Chlamydophila pneumoniae and Mycoplasma pneumoniae such that each pathogen could be detected in a single tube and differentiated using molecular beacons marked with different fluorochromes. This duplex PCR, targeting the P1 adhesion gene for M. pneumoniae and the ompA gene for C. pneumoniae, was compared with two conventional PCR assays targeting the 16S rRNA gene and the ompA gene. A total of 120 clinical throat and nasopharyngeal swab samples were tested. DNA extraction was performed using an alkali denaturation/neutralization method, and real-time amplification, detection, and data analysis were performed using a Rotor-Gene 2000 real-time rotary analyzer (Corbett Life Science, Sydney, Australia). Using conventional PCR as a reference in an analysis of 120 samples, 13 of 14 samples positive for C. pneumoniae were detected by the novel real-time PCR. In an analysis of M. pneumoniae, 22 samples were positive in the conventional PCR and the novel assay detected 24 positive samples. When using the conventional PCR as a reference, sensitivity and specificity were 93% and 100%, respectively, for C. pneumoniae and 100% and 98%, respectively, for M. pneumoniae. With an overall agreement of 98.8%, this suggests that performance of the new duplex real-time PCR is comparable to that of conventional PCR.


Chlamydophila pneumoniae and Mycoplasma pneumoniae are important and common causes of community-acquired pneumonia, where these pathogens are the etiological agent in 9 to 15% and 7 to 22% of cases, respectively (1, 14, 17, 19, 24, 29, 31). The highest incidence of C. pneumoniae and M. pneumoniae infections is among schoolchildren 5 to 14 years old (9, 16, 17, 23). Symptoms can be mild with nonproductive persistent cough, malaise, and fever, but more-severe illness occurs when the lower respiratory tracts are affected, giving rise to acute bronchitis and pneumonia (3, 10, 14). Cardiovascular disease and neurological diseases are serious nonrespiratory symptoms associated with C. pneumoniae and M. pneumoniae infections (4, 5, 11, 13, 28).

The agents causing respiratory infections are difficult to distinguish clinically, since many bacterial and viral infections often share clinical features, including symptoms (9, 22, 27). It is therefore important to find a sensitive and effective way of detecting these agents so that correct treatment will be offered and unnecessary use of antibiotic therapies avoided. C. pneumoniae and M. pneumoniae can show similar clinical features and share the characteristic of being difficult to diagnose using conventional methods, such as culture and serology. PCR has proven to be a fast and more-sensitive method and is therefore more widely used in clinical laboratories (6, 36). Recently several real-time PCR methods have been developed; these offer an even more advantageous way of detecting these pathogens (2, 15, 20, 25, 26, 30, 32, 35, 38). Real-time PCR has an advantage over conventional PCR because detection is performed in a closed system in real time, which minimizes the risk of contamination, and it is faster and requires less hands-on time.

In the present article, we describe a new duplex real-time PCR that can detect and distinguish both C. pneumoniae and M. pneumoniae in a single reaction tube. Detection is accomplished using two differently colored molecular-beacon probes that afford sensitive and specific detection.

MATERIALS AND METHODS

Bacterial strains and DNA.

Bacterial strains used for controls and tests of the specificities of the real-time PCR methods are listed in Table 1. Quantified C. pneumoniae and M. pneumoniae DNA samples were obtained from Advanced Biotechnologies, Inc. (Columbia, MD).

TABLE 1.

Species and strains used for specificity control

Species Strain or sourcea
Chlamydophila pneumoniae IOL 207
Mycoplasma pneumoniae ATCC 15531
Chlamydia psittaci Clinical isolate
Chlamydia trachomatis Bu434
Mycoplasma genitalium ATCC 33530
Bordetella parapertussis CCUG 413
Bordetella pertussis CCUG 33616
Candida albicans CCUG 32723
Enterobacter aerogenes CCUG 1429
Enterococcus faecalis ATCC 29212
Enterococcus faecium CCUG 542
Escherichia coli ATCC 25922
Haemophilus influenzae CCUG 23946
Haemophilus parainfluenzae CCUG 12836
Legionella pneumophila CCUG 9568
Moraxella catarrhalis CCUG 18283
Neisseria meningitidis CCUG 3269
Pseudomonas aeruginosa ATCC 27853
Staphylococcus aureus ATCC 29213
Staphylococcus epidermidis CCUG 18000
Stenotrophomonas maltophilia CCUG 5866
Streptococcus constellatus CCUG 24889
Streptococcus pneumoniae CCUG 33638
Streptococcus pyogenes CCUG 4207
a

ATCC, American Type Culture Collection; CCUG, Culture Collection University of Gothenburg, Gothenburg, Sweden.

Clinical samples.

A selection of 120 clinical samples was investigated. The samples had previously been analyzed with respect to either C. pneumoniae or M. pneumoniae or both, using two previously established PCR methods (7, 18). Selection and reanalysis of the samples were initiated to investigate several cases of possible false positives with respect to C. pneumoniae. Twenty-two samples previously defined as positive for M. pneumoniae and 66 samples previously defined as positive for C. pneumoniae were included, together with 32 samples previously defined as negative for both C. pneumoniae and M. pneumoniae when both PCR methods were used. Nasopharyngeal and throat swab samples from patients with respiratory tract infections were collected in 1997 and 1998 and in 2001 and 2002 at Gävle County Hospital.

The swab samples were transported in 2 ml sucrose phosphate buffer and were stored at −20°C until use. DNA extraction was performed on the suspension after the swabs were shaken vigorously in the buffer.

An additional 200 consecutive nasopharyngeal and throat swab samples collected in 2003 at Gävle County Hospital and shown to be negative for C. pneumoniae and M. pneumoniae when analyzed using the new real-time PCR were used to evaluate the rate and extent of PCR inhibition.

DNA extraction.

The Amplicor respiratory specimen preparation kit (Roche Diagnostics, Basel, Switzerland) was used as described previously (12), although in the present study, the wash procedure was simplified by adding 200 μl wash reagent directly to the 200-μl sample, which was mixed before it was centrifuged once, resulting in one rinse less than what is recommended by the manufacturer. Positive and negative controls were included in every extraction run. The extracted DNA was stored at −20°C until PCR was performed.

Conventional PCR.

Two conventional PCR procedures, used as routine methods at the laboratory, were compared with the novel assay. For detection of C. pneumoniae, a nested PCR, targeting the ompA gene, was used essentially as described by Tong and Sillis (34). The first reaction mixture contained 25 μl PCR Master kit (Roche Applied Science, Basel, Switzerland), 200 nM of each primer, and 10 μl template, giving a total volume of 50 μl. The second reaction mixture contained 25 μl PCR Master kit (Roche Applied Science, Basel, Switzerland), 400 nM of each primer, an additional 1.5 mM MgCl2, and 10 μl of a diluted template originating with the first reaction (1/10 and 1/500), giving a total volume of 50 μl. Samples were run in single reactions, and the cycling conditions for the first PCR in the nested method were 10 min at 94°C, a touchdown PCR of 30 s at 94°C, and 30 s of hybridization at 65°C, down to 55°C in steps of 1°C at every cycle and 60 s at 72°C. After the touchdown PCR, an additional 20 cycles were run for 30 s at 94°C, 30 s at 55°C, and 60 s at 72°C, with a final step of 5 min at 72°C. The cycling conditions for the nested PCR were 5 min at 94°C, 30 cycles of 30 s at 94°C, 30 s at 50°C, 60 s at 72°C, and one final step for 5 min at 72°C.

The conventional method for detection of M. pneumoniae, targeting the 16S rRNA, was performed essentially as described by van Kuppeveld et al. (37). The reaction mixture contained 2.5 μl PCR buffer (GE Healthcare Bio-Science AB, Uppsala, Sweden), 2 μl deoxynucleoside triphosphate (GE Healthcare Bio-Science AB, Uppsala, Sweden), 0.1 μl Taq polymerase (GE Healthcare Bio-Science AB, Uppsala, Sweden), an optical density at 260 nm of 0.625 for each primer, and 5 μl of template (undiluted and diluted 1/10), giving a total volume of 25 μl. The cycling conditions were 40 cycles of 30 s at 94°C, 30 s at 60°C, and 60 s at 72°C.

Amplification of both pathogens was performed using a Perkin-Elmer GeneAmp 9600 thermal cycler (Applied Biosystems, Foster City, CA). The PCR products (8 μl) were stained with ethidium bromide and visualized using UV light after gel electrophoresis on a 1.2% agarose gel.

Real-time PCR.

The novel real-time PCR methods were designed for a duplex PCR such that both pathogens can be detected and distinguished in one reaction tube using two sets of primers and two differently colored molecular beacon probes. The molecular beacons were designed using BioEdit, version 5.0.1 (http://www.ctu.edu.vn/∼dvxe/Bioinformatic/Software/BioEdit.htm), for sequence alignments and the Mfold DNA folding program (39). Accession numbers for sequences used were AF290002, M18639, AF290001, AF290000, M29372, M31431, and U39698 and AF184214, AF131230, AF131229, AF131889, S50607, M64064, and L04982 for Mycoplasma P1 adhesin genes and Chlamydophila ompA genes, respectively.

A BLAST search was performed to check the specificities of the DNA sequences for primers and probes (http://www.ncbi.nlm.nih.gov/BLAST, version 2.2.17). All oligonucleotides were synthesized by Thermo Electron Corporation (Ulm, Germany) and are shown in Table 2.

TABLE 2.

Primers and probes used for real-time detection of Chlamydophila pneumoniae and Mycoplasma pneumoniae

Primer or probea Target gene Primer or probe sequenceb Amplicon size (bp)
CPF ompA AGGCGTTGCTTTCCCCTTGCC 105
CPR ompA GATAGAGAGGCTCCTACTTGCCAT 105
CPP ompA FAM-GCGCTGGCTACTGGAACAAAGTCTGCGACCATCCAGCGC-Dabcyl 105
MPF P1 adhesion GCAGACGGTCGCGGATAACG 158
MPR P1 adhesion CGAACCAGGTGAGGTTGCCAATG 158
MPP1 P1 adhesion JOE-GCGCTGTCGGCCCCGATCGCCCTCCCGCAGCGC-Dabcyl 158
a

CP and MP indicate C. pneumoniae and M. pneumoniae, respectively; F and R indicate forward and reverse.

b

The underlined nucleotide sequence corresponds to the stem structure of the molecular beacon.

The reaction volume for real-time PCR was 25 μl, containing 12.5 μl HotstarTaq master mix (Qiagen, Hilden, Germany), 600 nM each of the CPR, MPR, and MPF primers, 200 nM of the CPF primer and each probe, and 5 μl of the DNA template. Clinical samples were run as duplicates, and the cycling conditions were 10 min at 95°C, followed by 50 cycles of 30 s at 95°C, 45 s at 55°C, and 20 s at 72°C. Amplification, detection, and data analysis were performed using a Rotor-Gene 2000 real-time rotary analyzer (Corbett Life Science, Sydney, Australia). Samples were regarded as positive if the two reactions or the majority of the reactions after reanalysis exceeded the fixed threshold of 0.01 normalized fluorescence units and showed an amplification curve.

Analytical performance of the real-time PCR.

Analytical sensitivity of the real-time PCR was determined by serially diluting quantified C. pneumoniae and M. pneumoniae DNA in a mixture of lysis and neutralization reagents (1:1) belonging to the DNA extraction kit. The concentrations tested were 100, 200, 250, 500, and 1,000 Geq/ml. The results of eight repeats of each concentration were then used to calculate the 95% probability of detection using PROBIT analysis. To evaluate whether coamplification and detection of C. pneumoniae and M. pneumoniae, respectively, would significantly lower the analytical sensitivity, mixtures of the two organisms were used as a template in the same reaction tube. A quantified DNA control for each organism at concentrations of 10 and 10,000 copies, respectively, per reaction was amplified together with 0, 10, and 10,000 copies per reaction of the other organism. The samples were run in triplicate, and the mean cycle-to-threshold values (CT values) and standard deviations were calculated. The rate and extent of PCR inhibition were estimated by spiking the clinical samples defined as negative. One hundred samples were spiked with the same amounts of the C. pneumoniae and M. pneumoniae DNA controls, respectively. A spiked sample found to be negative or with a CT value higher than 2 standard deviations above the mean CT value for all determinations was regarded as inhibitory to the PCR.

RESULTS

Analytical performance.

Specificity was confirmed when no signs of amplification were found when the organisms shown in Table 1 were tested using the real-time PCR. The analytical sensitivity was determined by PROBIT analysis of eight replicates in each concentration. The limits of detection, expressed as 95% probability of detection and 95% confidence limits, were 4.3 Geq/reaction (3.0 to 10.1) and 2.8 Geq/reaction (2.0 to 9.5) for C. pneumoniae and M. pneumoniae, respectively.

Both C. pneumoniae and M. pneumoniae were detected in reactions containing both pathogens. The CT values were not affected significantly when the reaction contained the other pathogen at a 1,000-fold excess compared to results when the detected pathogen was present in the tube alone, as shown in Table 3.

TABLE 3.

Sensitivity of duplex real-time PCR when coamplification was performed

Coamplification of DNA Detection (CT value) of DNA from:
C. pneumoniae
M. pneumoniae
10 copies 104 copies 10 copies 104 copies
None 33.9 ± 0.7 24.3 ± 0.08
M. pneumoniae (10 copies) 33.9 ± 0.7 24.5 ± 0.3
M. pneumoniae (104 copies) 32.2 ± 0.5 23.7 ± 0.02
None 30.2 ± 0.3 20.8 ± 0.3
C. pneumoniae (10 copies) 30.7 ± 0.2 20.5 ± 0.5
C. pneumoniae (104 copies) 29.9 ± 0.2 20.8 ± 0.05

Diagnostic performance.

All of the 100 samples spiked with C. pneumoniae were found to be positive and thus showed no sign of total inhibition. The mean CT value was 34.3 cycles. One of the samples had a CT value higher than 2 standard deviations above the mean CT value (>36.8 cycles), suggesting that it contained a factor that gives rise to partial inhibition of the PCR. There was no case of total inhibition in the 100 samples spiked with M. pneumoniae, although 4 samples showed signs of a partial inhibitory effect. The mean CT value for M. pneumoniae was 31.3 cycles, and samples were regarded as containing inhibitory factors if they exceeded 35 cycles. When the samples were diluted 20-fold, the inhibitory effect was no longer detectable.

Of the 120 clinical specimens, 13 samples were positive for C. pneumoniae and 22 samples were positive for M. pneumoniae when both the real-time duplex PCR and the conventional PCR were used. Retesting was performed with 10 out of 120 samples (6 M. pneumoniae samples and 5 C. pneumoniae samples) when only 1 positive reaction was found in the initial testing. After retesting, one of these samples was subsequently found to be positive using majority rule as described above (one positive for M. pneumoniae). Furthermore, one sample was positive for C. pneumoniae when the nested conventional PCR was used, and two additional samples were positive for M. pneumoniae when the real-time PCR was used. All three discrepant samples were sent for analysis using a third set of methods in an outside laboratory (Department of Clinical Microbiology, Capio Diagnostik AB, Kärnsjukhuset, Skövde, Sweden) (15, 20). Only one of the two samples positive for M. pneumoniae was confirmed. The sensitivity and specificity, when using the conventional PCR as a reference, were 93% and 100%, respectively, for C. pneumoniae. For M. pneumoniae, the sensitivity was 100% and the specificity was 98%. When the results from the discrepant samples were included, after analysis by the third set of methods, the sensitivity and specificity were 93% and 100%, respectively, for C. pneumoniae. For M. pneumoniae, the sensitivity was 100% and the specificity was 99%.

DISCUSSION

In the present study, we describe a newly constructed duplex real-time PCR that has the advantage of detecting C. pneumoniae and M. pneumoniae from a clinical sample using a single reaction tube. Using differently colored molecular beacon probes, the duplex detection is performed with high sensitivity and specificity. Both pathogens were detected with high sensitivity, and no cross-reaction with other tested species was observed.

The use of molecular-beacon probes enables specific detection, owing to the thermodynamics of the binding mechanisms. Such probes are also useful in multiplex reactions, since they show a low background signal. In a search for pathogens that give rise to similar clinical features, the multiplex approach is advantageous because it saves time, reagents, and use of equipment (21). The drawback of multiplex PCR assays is the phenomenon of competition between simultaneous amplification reactions of nucleic acid templates from several different pathogens in the same tube. This could affect detection of a dual infection, especially if one of the pathogens is found in a larger quantity than the other (21). Coinfection of C. pneumoniae and M. pneumoniae is rare, but it has been described (22, 38). From the 120 clinical samples tested in the present study, none tested positive for both C. pneumoniae and M. pneumoniae when real-time PCR or conventional PCR was used. Based on the current rates of positive samples seen at our laboratories, coinfection can be expected in 1 of 1,800 samples. Although the influence on analytical performance in dual detection of both pathogens was investigated, no significant effect on CT values was revealed when pathogens were present in a 1,000-fold excess compared to CT values achieved when only 1 of the pathogens was present. The multiple target amplification did not reduce the analytical sensitivity of the real-time PCR method, which is consistent with the results of Welti et al. (38). Another drawback of multiplex PCR is that its analytical sensitivity could be lower than that of monoplex PCR, owing to the complexity of optimizing the multiple variables to achieve optimal conditions for all included PCRs (33). The analytical sensitivity achieved for both pathogens using this duplex real-time PCR method was comparable to the high sensitivity described for other real-time PCR methods (20, 25, 32, 38).

In the present study, the Amplicor preparation kit was used as the DNA extraction method because it has previously been shown to be appropriate for this type of material and pathogens (12; data not shown). The choice of DNA extraction can influence PCR sensitivity and rates of inhibition, which can easily be monitored using real-time PCR. None of the 200 swab samples spiked with a small amount of C. pneumoniae or M. pneumoniae was inhibited for detection, although 2.5% of the samples showed partial inhibition.

A comparison between this duplex real-time PCR and two previously described conventional PCR methods (34, 37) showed an overall agreement of 98.8% when 120 clinical swab samples were tested. Of these 120 samples, 13 were positive for C. pneumoniae when both methods were used and 1 additional sample was positive when the conventional nested touchdown PCR was used, suggesting that the nested PCR is more sensitive than is the real-time PCR. The same target gene, ompA, is used in both methods, and nested PCR is generally recognized to have high sensitivity (8). However, it is important to consider that nested PCR entails a high risk of carryover contaminations, which cannot be completely eliminated even when appropriate precautions are taken.

Different target genes were used in the real-time PCR assay and the conventional assay for M. pneumoniae: the P1 adhesion gene and the 16S rRNA gene, respectively. A total of 22 samples were positive for M. pneumoniae with both assays, and an additional 2 samples were positive when the real-time PCR was used but negative when conventional PCR was used, suggesting that the real-time PCR could be a more sensitive method. However, it was possible to reproduce only one of these discrepant results using a separate set of methods in an independent laboratory (15, 20).

In conclusion, this new duplex real-time PCR can specifically detect and distinguish C. pneumoniae and M. pneumoniae in clinical samples with high sensitivity. Molecular-beacon probes are successfully used in this duplex setting to detect both pathogens in the same sample. This is of great clinical value, since the symptoms of C. pneumoniae and M. pneumoniae are often difficult to distinguish.

Acknowledgments

We thank Hans Högberg at the Centre for Research & Development, Uppsala University/County Council of Gävleborg, for helping us with statistical calculations. We also thank Helena Enroth and colleges at the Department of Clinical Microbiology, Capio Diagnostik AB, Kärnsjukhuset, Skövde, for assistance in validation of the method.

The work described in this report was supported by grants from the Uppsala and Gävleborg County Council (to K.B. and K.G.).

Footnotes

Published ahead of print on 19 December 2007.

REFERENCES

  • 1.Almirall, J., I. Morato, F. Riera, A. Verdaguer, R. Priu, P. Coll, J. Vidal, L. Murgui, F. Valls, F. Catalan, et al. 1993. Incidence of community-acquired pneumonia and Chlamydia pneumoniae infection: a prospective multicentre study. Eur. Respir. J. 614-18. [PubMed] [Google Scholar]
  • 2.Apfalter, P., W. Barousch, M. Nehr, A. Makristathis, B. Willinger, M. Rotter, and A. M. Hirschl. 2003. Comparison of a new quantitative ompA-based real-time PCR TaqMan assay for detection of Chlamydia pneumoniae DNA in respiratory specimens with four conventional PCR assays. J. Clin. Microbiol. 41592-600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Atmar, R. L., and S. B. Greenberg. 1989. Pneumonia caused by Mycoplasma pneumoniae and the TWAR agent. Semin. Respir. Infect. 419-31. [PubMed] [Google Scholar]
  • 4.Bitnun, A., E. L. Ford-Jones, M. Petric, D. MacGregor, H. Heurter, S. Nelson, G. Johnson, and S. Richardson. 2001. Acute childhood encephalitis and Mycoplasma pneumoniae. Clin. Infect. Dis. 321674-1684. [DOI] [PubMed] [Google Scholar]
  • 5.Boelen, E., H. W. Steinbusch, A. J. van der Ven, G. Grauls, C. A. Bruggeman, and F. R. Stassen. 2007. Chlamydia pneumoniae infection of brain cells: an in vitro study. Neurobiol. Aging 28524-532. [DOI] [PubMed] [Google Scholar]
  • 6.Boman, J., A. Allard, K. Persson, M. Lundborg, P. Juto, and G. Wadell. 1997. Rapid diagnosis of respiratory Chlamydia pneumoniae infection by nested touchdown polymerase chain reaction compared with culture and antigen detection by EIA. J. Infect. Dis. 1751523-1526. [DOI] [PubMed] [Google Scholar]
  • 7.Campbell, L. A., M. Perez Melgosa, D. J. Hamilton, C. C. Kuo, and J. T. Grayston. 1992. Detection of Chlamydia pneumoniae by polymerase chain reaction. J. Clin. Microbiol. 30434-439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Dowell, S. F., R. W. Peeling, J. Boman, G. M. Carlone, B. S. Fields, J. Guarner, M. R. Hammerschlag, L. A. Jackson, C. C. Kuo, M. Maass, T. O. Messmer, D. F. Talkington, M. L. Tondella, and S. R. Zaki. 2001. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin. Infect. Dis. 33492-503. [DOI] [PubMed] [Google Scholar]
  • 9.Foy, H. M. 1993. Infections caused by Mycoplasma pneumoniae and possible carrier state in different populations of patients. Clin. Infect. Dis. 17(Suppl. 1)S37-S46. [DOI] [PubMed] [Google Scholar]
  • 10.Gaillat, J., A. Flahault, B. deBarbeyrac, J. Orfila, H. Portier, J. P. Ducroix, C. Bebear, and C. Mayaud. 2005. Community epidemiology of Chlamydia and Mycoplasma pneumoniae in LRTI in France over 29 months. Eur. J. Epidemiol. 20643-651. [DOI] [PubMed] [Google Scholar]
  • 11.Gnarpe, H., J. Gnarpe, B. Gastrin, and H. Hallander. 1997. Chlamydia pneumoniae and myocarditis. Scand. J. Infect. Dis. Suppl. 10450-52. [PubMed] [Google Scholar]
  • 12.Gnarpe, J., and K. Eriksson. 1995. Sample preparation for Chlamydia pneumoniae PCR. APMIS 103307-308. [PubMed] [Google Scholar]
  • 13.Grayston, J. T. 2000. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J. Infect. Dis. 181(Suppl. 3)S402-S410. [DOI] [PubMed] [Google Scholar]
  • 14.Grayston, J. T., L. A. Campbell, C. C. Kuo, C. H. Mordhorst, P. Saikku, D. H. Thom, and S. P. Wang. 1990. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J. Infect. Dis. 161618-625. [DOI] [PubMed] [Google Scholar]
  • 15.Hardegger, D., D. Nadal, W. Bossart, M. Altwegg, and F. Dutly. 2000. Rapid detection of Mycoplasma pneumoniae in clinical samples by real-time PCR. J. Microbiol. Methods 4145-51. [DOI] [PubMed] [Google Scholar]
  • 16.Heath, P. T. 2000. Epidemiology and bacteriology of bacterial pneumonias. Paediatr. Respir. Rev. 14-7. [DOI] [PubMed] [Google Scholar]
  • 17.Heiskanen-Kosma, T., M. Korppi, A. Laurila, C. Jokinen, M. Kleemola, and P. Saikku. 1999. Chlamydia pneumoniae is an important cause of community-acquired pneumonia in school-aged children: serological results of a prospective, population-based study. Scand. J. Infect. Dis. 31255-259. [DOI] [PubMed] [Google Scholar]
  • 18.Jensen, J. S., J. Sondergard-Andersen, S. A. Uldum, and K. Lind. 1989. Detection of Mycoplasma pneumoniae in simulated clinical samples by polymerase chain reaction. Brief report. APMIS 971046-1048. [DOI] [PubMed] [Google Scholar]
  • 19.Korppi, M., T. Heiskanen-Kosma, and M. Kleemola. 2004. Incidence of community-acquired pneumonia in children caused by Mycoplasma pneumoniae: serological results of a prospective, population-based study in primary health care. Respirology 9109-114. [DOI] [PubMed] [Google Scholar]
  • 20.Kuoppa, Y., J. Boman, L. Scott, U. Kumlin, I. Eriksson, and A. Allard. 2002. Quantitative detection of respiratory Chlamydia pneumoniae infection by real-time PCR. J. Clin. Microbiol. 402273-2274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Markoulatos, P., N. Siafakas, and M. Moncany. 2002. Multiplex polymerase chain reaction: a practical approach. J. Clin. Lab. Anal. 1647-51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Marrie, T. J., R. W. Peeling, M. J. Fine, D. E. Singer, C. M. Coley, and W. N. Kapoor. 1996. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am. J. Med. 101508-515. [DOI] [PubMed] [Google Scholar]
  • 23.McIntosh, K. 2002. Community-acquired pneumonia in children. N. Engl. J. Med. 346429-437. [DOI] [PubMed] [Google Scholar]
  • 24.Michelow, I. C., K. Olsen, J. Lozano, N. K. Rollins, L. B. Duffy, T. Ziegler, J. Kauppila, M. Leinonen, and G. H. McCracken, Jr. 2004. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 113701-707. [DOI] [PubMed] [Google Scholar]
  • 25.Morozumi, M., E. Nakayama, S. Iwata, Y. Aoki, K. Hasegawa, R. Kobayashi, N. Chiba, T. Tajima, and K. Ubukata. 2006. Simultaneous detection of pathogens in clinical samples from patients with community-acquired pneumonia by real-time PCR with pathogen-specific molecular beacon probes. J. Clin. Microbiol. 441440-1446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Raggam, R. B., E. Leitner, J. Berg, G. Muhlbauer, E. Marth, and H. H. Kessler. 2005. Single-run, parallel detection of DNA from three pneumonia-producing bacteria by real-time polymerase chain reaction. J. Mol. Diagn. 7133-138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Saikku, P. 1997. Atypical respiratory pathogens. Clin. Microbiol. Infect. 3599-604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Saikku, P. 1996. Chlamydia pneumoniae and cardiovascular diseases. Clin. Microbiol. Infect. 1(Suppl. 1)S19-S22. [DOI] [PubMed] [Google Scholar]
  • 29.Sundelof, B., J. Gnarpe, H. Gnarpe, L. Grillner, and S. Darougar. 1993. Chlamydia pneumoniae in Swedish patients. Scand. J. Infect. Dis. 25429-433. [DOI] [PubMed] [Google Scholar]
  • 30.Templeton, K. E., S. A. Scheltinga, A. W. Graffelman, J. M. Van Schie, J. W. Crielaard, P. Sillekens, P. J. Van Den Broek, H. Goossens, M. F. Beersma, and E. C. Claas. 2003. Comparison and evaluation of real-time PCR, real-time nucleic acid sequence-based amplification, conventional PCR, and serology for diagnosis of Mycoplasma pneumoniae. J. Clin. Microbiol. 414366-4371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Thom, D. H., J. T. Grayston, S. P. Wang, C. C. Kuo, and J. Altman. 1990. Chlamydia pneumoniae strain TWAR, Mycoplasma pneumoniae, and viral infections in acute respiratory disease in a university student health clinic population. Am. J. Epidemiol. 132248-256. [DOI] [PubMed] [Google Scholar]
  • 32.Tondella, M. L., D. F. Talkington, B. P. Holloway, S. F. Dowell, K. Cowley, M. Soriano-Gabarro, M. S. Elkind, and B. S. Fields. 2002. Development and evaluation of real-time PCR-based fluorescence assays for detection of Chlamydia pneumoniae. J. Clin. Microbiol. 40575-583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Tong, C. Y., C. Donnelly, G. Harvey, and M. Sillis. 1999. Multiplex polymerase chain reaction for the simultaneous detection of Mycoplasma pneumoniae, Chlamydia pneumoniae, and Chlamydia psittaci in respiratory samples. J. Clin. Pathol. 52257-263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Tong, C. Y., and M. Sillis. 1993. Detection of Chlamydia pneumoniae and Chlamydia psittaci in sputum samples by PCR. J. Clin. Pathol. 46313-317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Ursi, D., K. Dirven, K. Loens, M. Ieven, and H. Goossens. 2003. Detection of Mycoplasma pneumoniae in respiratory samples by real-time PCR using an inhibition control. J. Microbiol. Methods 55149-153. [DOI] [PubMed] [Google Scholar]
  • 36.van Kuppeveld, F. J., K. E. Johansson, J. M. Galama, J. Kissing, G. Bolske, E. Hjelm, J. T. van der Logt, and W. J. Melchers. 1994. 16S rRNA based polymerase chain reaction compared with culture and serological methods for diagnosis of Mycoplasma pneumoniae infection. Eur. J. Clin. Microbiol. Infect. Dis. 13401-405. [DOI] [PubMed] [Google Scholar]
  • 37.van Kuppeveld, F. J., J. T. van der Logt, A. F. Angulo, M. J. van Zoest, W. G. Quint, H. G. Niesters, J. M. Galama, and W. J. Melchers. 1992. Genus- and species-specific identification of mycoplasmas by 16S rRNA amplification. Appl. Environ. Microbiol. 582606-2615. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Welti, M., K. Jaton, M. Altwegg, R. Sahli, A. Wenger, and J. Bille. 2003. Development of a multiplex real-time quantitative PCR assay to detect Chlamydia pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae in respiratory tract secretions. Diagn. Microbiol. Infect. Dis. 4585-95. [DOI] [PubMed] [Google Scholar]
  • 39.Zuker, M. 2003. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 313406-3415. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES